New hope for Tough-to-Treat myeloma: early trial of OPN-6602 begins
Disease control
Recruiting now
This early-phase study tests a new drug called OPN-6602, given alone or with another drug (dexamethasone), in people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The main goal is to check the drug's safety and find the right dose. …
Phase: PHASE1 • Sponsor: Opna Bio LLC • Aim: Disease control
Last updated May 26, 2026 10:29 UTC